Semaglutide,Long-lasting blood sugar reduction, Powerful weight loss

We are supplying all of our  foreign customers with Customized Pharmaceutical Formulations or Dosage Forms.

You can tell us any pharmaceutical product, no matter what it is that you want. And then we will give you a detailed solution as per your requirement.  

Semaglutide is a long-acting GLP-1 receptor agonist. Its core values lie in long-lasting blood sugar reduction, powerful weight loss, and cardiovascular protection. It has been approved by many countries around the world for the long-term management of type 2 diabetes and obesity/overweight.

Mechanism of action and core advantages
1. Core mechanism
Glucose-dependent secretion promotion, glucagon inhibition, and stable blood sugar reduction;

Delay gastric emptying + activate the central appetite center, significantly increasing satiety and reducing calorie intake;

Improve lipid metabolism (reduce LDL-C), protect cardiovascular endothelium, and lower the risk of MACE;

Long-acting structural modification (binding to albumin + anti-DPP-4 degradation) enables once-weekly administration.

2. Key clinical data
Hypoglycemic: The average reduction in HbA1c in patients with type 2 diabetes is 1.5% to 1.8%, which is superior to that of traditional hypoglycemic drugs.

Weight loss: The average weight loss after 52 weeks of treatment is 10% to 15%, and more than 30% of patients lose at least 15%.

Cardiovascular: Reduces the risk of major adverse cardiovascular events by approximately 26% (SUSTAIN-6 trial).

Iii. Administration Regimens and Dosage Adjustments
Special adjustments for population/dosage form initiation period, incremental period, maintenance period
Type 2 diabetes (injection) : 0.25mg/week ×4 weeks, 0.5mg/week ×4 weeks, up to 1mg/week, 1mg/week (maximum). For renal insufficiency, the initial dose should be halved

Obesity/Overweight (injection) 0.25mg/week ×4 weeks, doubling every 4 weeks (0.5→1→1.7mg) 2.4mg/week (maximum) Intolerance can fall back to 1.7mg

Iv. Safety and Precautions
Common adverse reactions (mild to moderate, relieved with treatment)
Gastrointestinal tract: Nausea (30%), diarrhea (20%), constipation (10%), vomiting (8%);

Others: Headache (7%), fatigue (5%), injection site reaction (4%);

Hypoglycemia: The risk increases when used in combination with sulfonylureas. The dosage should be reduced and blood sugar monitored.

2. Taboos and Risks
Contraindications: History of medullary thyroid carcinoma (MTC) or family history, MEN type 2, allergic individuals, pregnant or lactating women;
Warning: It may increase the risk of pancreatitis and gallbladder diseases. Long-term monitoring of thyroid function (CT/CgA) is required.
Special populations: Type 1 diabetes, children (under 12 years old) contraindicated. Elderly patients do not need to adjust the dosage.

3. Drug interactions
When used in combination with drugs that delay gastric emptying (such as opioids), it may affect absorption and should be administered at intervals.
The oral version should not be taken concurrently with proton pump inhibitors, as it may reduce bioavailability.